US eye care company ISTA Pharmaceuticals announced plans to file an investigational new drug (IND) application with the FDA for its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis by the end of 2010. The company also released results from a Phase I/II study of the nasal spray showing that the drug was well tolerated and said that it plans to begin a new Phase II study this year. ISTA licensed North American rights to both opthalmic and nasal formulations of bepotastine besilate from Tanabe Seiyaku in 2006-2007. Read the company’s press release.
